m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02895)
Name
(4-Phenoxy-phenyl)-quinazolin-4-yl-amine
Synonyms
CHEMBL304760; N-(4-phenoxyphenyl)quinazolin-4-amine; (4-Phenoxy-phenyl)-quinazolin-4-yl-amine; AC1LEH7Z; Neuro1_000298; Oprea1_168469; SCHEMBL5568872; MolPort-000-668-533; ZINC104659; BDBM50092231; STK918072; (4-phenoxyphenyl)quinazolin-4-ylamine; AKOS002241807; N-(4-Phenoxyphenyl)-4-quinazolinamine; MCULE-2087445269; ST50197248; EU-0074581; SR-01000459365
    Click to Show/Hide
Status
Investigative
Structure
Formula
C20H15N3O
InChI
1S/C20H15N3O/c1-2-6-16(7-3-1)24-17-12-10-15(11-13-17)23-20-18-8-4-5-9-19(18)21-14-22-20/h1-14H,(H,21,22,23)
InChIKey
RJOICMFRJBMONF-UHFFFAOYSA-N
PubChem CID
712152
TTD Drug ID
D07AIB
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Angiopoietin 1 receptor (TEK)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Angiopoietin 1 receptor (TEK) is a therapeutic target for (4-Phenoxy-phenyl)-quinazolin-4-yl-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (4-Phenoxy-phenyl)-quinazolin-4-yl-amine through regulating the expression of Angiopoietin 1 receptor (TEK). [1], [2]
References
Ref 1 Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis. Front Cell Dev Biol. 2021 Feb 18;9:627706. doi: 10.3389/fcell.2021.627706. eCollection 2021.
Ref 2 A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6. doi: 10.1016/j.bmcl.2004.02.101.